Dr Adam ChambersSenior Scientific Officer
Adam completed his BSc in Biotechnology at Oxford Brookes University. His third year was spent working on placement with Professor Possee at the Centre of Ecology and Hydrology (CEH) in Oxford on insect baculovirus molecular biology. After the final year of his degree he embarked upon a PhD at Oxford Brookes University with Professor Linda King. His research project concerned the role of ODV structural proteins in baculovirus replication. Following his PhD, Adam joined OET in 2010 as a junior scientist but is now one of the senior scientists within the company and oversees the successful running of the laboratory facilities and its research staff.
Olga LissianaSenior Scientific Officer
Olga was educated in Russia at Gorky State University, where she was awarded an MSc in BioPhysics. After working for 14 years at several Russian Academy of Sciences Institutes, she joined CEH Oxford where she gained an enviable reputation for establishing a range of innovative procedures for purifying proteins with putative therapeutic potency expressed in bacterial, yeast and baculovirus expression systems. She participated in technology transfer for industrial scale protein production as well as advising companies producing proteins for clinical trials. From CEH she moved to the Oxford Structural Genomics Consortium before joining OET in 2007 to set up a protein purification service. Her skills also include maintaining the OET insect cell bank for use in house and to provide cryopreserved cells to customers.
Dr Mine AksularPost-Doctoral Research Assistant
Mine completed her BSc in Biomedical Sciences at Oxford Brookes University where she first gained an interest in baculovirus research whilst carrying out her undergraduate project with Prof Linda King. She then moved to London to study for her MSc in Infection and Immunity at the University College London before securing a PhD position as part of a collaboration between Oxford Brookes University, the BBSRC Pirbright Institute and OET. This project concerned investigating the antigenic structure of African horse sickness virus (AHSV) VP2 protein which provides the groundwork for generating baculovirus-based AHSV vaccines. Mine came to work for OET in 2016 and carries out essential research in the production of a vaccine towards CCHF virus and also the development of gene therapies against type I diabetes.
Dr Leo GravesPost-Doctoral Research Assistant
Leo received his BSc in Biotechnology at Oxford Brookes University, which included a year’s placement working at the Centre of Ecology and Hydrology (CEH). After this he started work at Allergy Therapeutics as part of the quality control and research & development division. He was then accepted for a funded PhD position at Oxford Brookes University to work with Prof Linda King on understanding the functional role of a highly expressed baculovirus protein, P10. Shortly afterwards Leo joined OET part-time in 2017 before moving to full-time employment in early 2018. He currently works on company service projects as well as OET’s UK-Mexico collaboration (TRANSDIA) to investigate the use of baculovirus in the development of gene therapies for diabetes type I.
Dr Raquel Arinto GarciaPost-Doctoral Research Assistant
Raquel completed her BSc in Health Sciences at Lisbon University and her MSc in Medical Microbiology at the New University of Lisbon where she first gained an interest in medical science research. She then moved to Oxford for a funded PhD position at Oxford Brookes University to work with Prof Robert Possee on understanding the mechanisms of establishment and maintenance of baculovirus persistent infections in insect cells. Raquel came to work for OET in March of 2019 and works on company service projects as well as research and development of new OET flashBAC products.
Durva SevakScientific Officer
Durva completed a degree in Biomedical Science at Oxford Brookes University before undertaking an MRes degree in Cancer Sciences at Birmingham University. Her area of research concerned a novel gene with a potential role in the Fanconi Anaemia tumour suppressor pathway. After finishing her studies, Durva joined OET in 2016 to work exclusively on the applications of baculovirus technology in the production of a viable vaccine for CCHF virus. Her involvement with the project from the outset has provided extensive experience and knowledge which will be beneficial as she continues to provide support during the next stage of its development.
Cassandra RigbyScientific Officer
Cassandra finished her BSc in Pharmacology at King’s College London. The duration of her third year was spent completing an industrial placement at MRC Technology (now LifeArc) working on developing small molecule inhibitors against a metabolic target for the treatment of metastatic breast cancer. After leaving university she worked for 6 months at QuintilesIMS (now IQVIA) as a clinical trial research assistant where she gained experience in Phase I-III clinical trials. Cassandra joined OET in early 2018 to provide research assistance for the second stage of the CCHF vaccine project.